<?xml version="1.0" encoding="UTF-8"?>
<p id="par0190">Combining all in-vitro and in-vivo data, some countries have authorized treating hospitalized patients, with some conditions, with CQ and HCQ [
 <xref rid="bib0110" ref-type="bibr">22</xref>,
 <xref rid="bib0135" ref-type="bibr">27</xref>,
 <xref rid="bib0140" ref-type="bibr">28</xref>]. However, there are serious concerns raised regarding its usage. For example, clinical data from reliable randomized controlled studies are still missing, and data published to date lacks homogeneity in terms of recommended dose concentration, treatment duration, and severity of patient illness [
 <xref rid="bib0290" ref-type="bibr">58</xref>].
</p>
